医学
原发性甲状旁腺功能亢进
西那卡塞特
德诺苏马布
甲状旁腺功能亢进
内分泌疾病
疾病
甲状旁腺
拟钙质
内分泌系统
甲状旁腺激素
外科
重症监护医学
继发性甲状旁腺功能亢进
内科学
激素
骨质疏松症
钙
出处
期刊:PubMed
日期:2017-10-06
卷期号:27 (4): 553-559
摘要
Primary hyperparathyroidism is a common endocrine disease. The first line therapy for the disease is surgical removal of affected parathyroid gland(s). Other therapeutic options with medication are needed to be established, because many of patients with primary hyperparathyroidism have few or no symptoms and are expected to have a long life expectancy without surgery. Cinacalcet as a calcimimetic, bisphosphonates and denosumab are promising candidates for medical management of the disease. Effectiveness and efficiency of these drugs for patients with primary hyperparathyroidism is to be evaluated in comparison with surgical treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI